Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock

This article was originally published in The Tan Sheet

Executive Summary

An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January

You may also be interested in...



Plan B ANPR Comments Undergoing Independent Contractor Review

Plan B comment analysis is being handled by an outside contractor with oversight by FDA's Office of Policy, according to Acting Commissioner Andrew von Eschenbach, MD

Plan B ANPR Comments Undergoing Independent Contractor Review

Plan B comment analysis is being handled by an outside contractor with oversight by FDA's Office of Policy, according to Acting Commissioner Andrew von Eschenbach, MD

Plan B ANPR Comments Undergoing Independent Contractor Review

Plan B comment analysis is being handled by an outside contractor with oversight by FDA's Office of Policy, according to Acting Commissioner Andrew von Eschenbach, MD

Related Content

Topics

UsernamePublicRestriction

Register

PS097080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel